Advertisement
News
Subscribe to MDT Magazine News

Novartis halts lung cancer trial

November 11, 2010 9:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Novartis AG said it is discontinuing late stage clinical trials for a drug candidate to treat lung cancer because the trial was unlikely to meet its endpoint.

TOPICS:

Dehaier Medical Announces Conference Call to Discuss Third Quarter 2010 Financial Results

November 11, 2010 9:34 am | by Bio-Medicine.Org | Comments

BEIJING, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it will hold...

TOPICS:

Mindray Medical to Exhibit at MEDICA 2010 in Dusseldorf, Germany from November 17- 20, 2010

November 11, 2010 9:34 am | by Bio-Medicine.Org | Comments

SHENZHEN, China, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR ), a leading developer, manufacturer and marketer of medical devices worldwide, today announced its participation in the MEDICA 2010 42nd World Forum of Medicine International...

TOPICS:
Advertisement

IPC buys Nevada doctor group for undisclosed sum

November 11, 2010 6:45 am | by The Associated Press | Comments

IPC The Hospitalist Company Inc. said Thursday it bought the Las Vegas physician group practice Zenith Hospitalists. Terms of the deal were not disclosed.IPC, a physician group practice company, said the deal expands its presence in a Nevada market where it is already well-established. Zenith...

MedClean Technologies Signs Contract with Gamma HealthCare Inc./Danner Medical Waste for MedClean 4500 Fixed-Based System, Services, and Consumables

November 11, 2010 5:36 am | by Bio-Medicine.Org | Comments

BETHEL, Conn., Nov. 11, 2010 /- MedClean Technologies (OTC Bulletin Board: MCLN ), the leading provider of onsite technology for the treatment and disposal of medical waste and the destruction of confidential documents and related media, today announced it has signed an agreement with...

TOPICS:

Frost & Sullivan Recognizes Merge Healthcare's Clinical Imaging Management Solution as 'Game Changing Technology'

November 11, 2010 5:36 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., Nov. 11, 2010 /- Based on its recent analysis of the medical imaging workflow solutions market, Frost & Sullivan recognizes Merge Healthcare with the 2010 North American Frost & Sullivan Award for Healthcare Innovation of the Year for the Clinical Imaging...

TOPICS:

Thoratec Announces Webcast of Investor Presentation at American Heart Association Meeting

November 11, 2010 5:35 am | by Bio-Medicine.Org | Comments

PLEASANTON, Calif., Nov. 11, 2010 /- Thoratec Corporation (Nasdaq: THOR ), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be hosting an investor event on Tuesday, November 16 at the American Heart...

TOPICS:

Philips Announces Its Portfolio of Lifesaving Solutions Supports New American Heart Association 2010 CPR and ECC Guidelines

November 11, 2010 5:34 am | by Bio-Medicine.Org | Comments

ANDOVER, Mass., Nov. 11, 2010 /- Royal Philips Electronics (NYSE: PHG; AEX: PHI), a worldwide leader in defibrillation technology, today announced that its entire line of emergency care and resuscitation solutions supports the newly updated American Heart Association Guidelines for...

TOPICS:
Advertisement

NIAID media tipsheet: Annual Meeting of the American College of Allergy, Asthma and Immunology

November 11, 2010 5:34 am | by EurekAlert | Comments

(NIH/National Institute of Allergy and Infectious Diseases) Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will present their latest research findings at the ACAAI Annual Meeting. For more than 60...

TOPICS:

New Screening Approach FIT to Fight Colorectal Cancer in the U.S.

November 11, 2010 5:34 am | by Bio-Medicine.Org | Comments

CORTLANDT MANOR, N.Y., Nov. 11, 2010 /- Colorectal cancer (CRC) are two words that most people don't want to talk or even think about. But for 50,000 Americans every year, the disease takes their life. Colorectal cancer is the second leading cause of cancer-related death; a figure that...

TOPICS:

Vermillion Reports Financial Results for the Third Quarter 2010

November 11, 2010 5:34 am | by Bio-Medicine.Org | Comments

AUSTIN, Texas, Nov. 11, 2010 /- Vermillion, Inc. (Nasdaq: VRML ), a molecular diagnostics company, today reported financial results for the third quarter ended September 30, 2010. Key milestones achieved since our last quarterly conference call include: Performed 1,973 OVA1...

TOPICS:

CTRC-AACR San Antonio Breast Cancer Symposium to Hold 33rd Annual Symposium

November 11, 2010 5:33 am | by AACR | Comments

The 33rd CTRC-AACR San Antonio Breast Cancer Symposium will feature the latest findings in prevention, epidemiological, laboratory, translational and clinical breast cancer research. This year’s symposium will highlight new therapies in the pipeline, new approaches with existing agents...

TOPICS:

Tobii Technology Launches 300 Hz Eye Tracker That Gives Subjects Room to Move, Opens Up Possibilities for New Fields of Research

November 11, 2010 4:35 am | by RealWire | Comments

New TX300 to help scientists create studies that capture saccades, micro saccades and fixations at 300 hertz while allowing for subjects' natural head movement Stockholm & Washington, Nov. 11, 2010 - Tobii Technology, the global market leader in eye tracking, announced today its new...

TOPICS:

Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock

November 11, 2010 1:36 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Nov. 11, 2010 /- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ) today announced that it has priced an underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $8.00 per share.  The net proceeds from the sale of the shares, after...

TOPICS:

ImmunGene's Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today

November 11, 2010 1:36 am | by Bio-Medicine.Org | Comments

THOUSAND OAKS, Calif., Nov. 11, 2010 /- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading